30 results about "Aqueous buffer" patented technology

An embolic hydrogel for a patient comprises an aqueous buffer and at least one functionalized polymer, each having at least one polymer backbone chemically modified with one or more functional groups. The functional groups facilitate the formation of a primary reversible cross-link on the polymer backbone such that the embolic hydrogel transitions from a gel state to a viscous liquid state in response to shear forces applied to the embolic hydrogel and transitions from the viscous liquid state to the gel state in response to the absence of shear forces applied to the embolic hydrogel. The embolic hydrogel also includes at least one phase change polymer that produces secondary crosslinking therein in response to a physiological environment such that the embolic hydrogel transitions from a gel state to a solid state.

The present disclosure provides a rapid, facile, economical, and highly scalable method for producing selenoneine. The method involves SenA, hercynine, a selenosugar, and optionally a reductant, and a single, high-yielding enzymatic step in, e.g., a neutral-pH aqueous buffer and at ambient temperature. It can achieve yields of around 5 grams selenoneine per liter reaction with approximate costs of $100 per gram selenoneine.

A rapid, field-deployable method and associated kit for the qualitative detection of zinc fortification in wheat flour are disclosed. ፐከ6 method includes treating a wheat flour sample suspected of containing added zinc with a chromogenic reagent comprising dithizone dissolved in an ethanol solvent to induce a visually discernible color change from a blue profile to a pink-purple or red profile. The assay can be performed 85 8 surface spot test or as ል testtube liquid assay, the latter utilizing an aqueous buffer solution maintained at a pH of 5.5 to 6.0 to mobilize zinc ions. The resulting color change is evaluated against an intentionally fortified wheat flour standard. When validated against an Inductively Coupled Plasma Mass Spectrometry (ICP-MS) reference standard, the assay exhibits a sensitivity of 96.5%, a specificity of 90.9%, an overall misclassification rate of 5.88%, and 8 Cohen's kappa coefficient (k) of 0.88.

The invention provides a lipidosome adjuvant system based on furanose type QS-21 saponin molecules and a preparation method. The lipidosome adjuvant system comprises lipidosome and the QS-21 saponin molecules, the lipidosome comprises a lipid bilayer formed by ionizable lipid, structural phospholipid and cholesterol, the QS-21 saponin molecule is in a furanose type and is loaded on the lipidosome, and the QS-21 saponin molecule is partially inserted into the lipid bilayer through hydrophobic triterpenoid aglycone of the QS-21 saponin molecule. The preparation method comprises the following steps: dissolving lipidosome components forming lipid bilayers in an organic solvent to form a lipid phase, dissolving furanose type QS-21 saponin molecules in an acidic aqueous phase buffer solution to form a QS-21 aqueous phase, mixing the lipid phase and the QS-21 aqueous phase, precipitating lipid, and self-assembling to form lipidosome nanoparticles loaded with furanose type QS-21 saponin molecules, and finally, purifying to remove the organic solvent and the unencapsulated QS-21 molecules. According to the invention, through well-designed lipid composition and a preparation process, furanose type QS21 molecules are stably integrated into the lipidosome.

The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition / solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular a source of ions of K; preparing a second composition / solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of K, said compositions / solutions 1 and 2 being free of any organic structure directing agent; -mixing the composition / solutions 1 and 2 and standing under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating said nanoparticles formed. According to the invention, both the first composition / solution 1 and the second composition / solution 2 consist of said source and an aqueous buffer. The invention also relates to colloidal suspensions of the resulting nanoparticles, and to pharmaceutical compositions comprising said nanoparticles.

This invention discloses an N-substituted pyridine fluoroborate inner salt reagent, its preparation method, and its application in the preparation of F-18 radiopharmaceuticals. The N-substituted pyridine fluoroborate inner salt reagent is obtained by reacting protonated pyridine fluoroborate of Formula I with a compound of Formula II in the presence of a solvent. This inner salt reagent, through a substituted alkyl group linked to the pyridine N-phase, can undergo a coupling reaction with molecules containing specific groups (including drug molecules or their derivatives) to generate F-18 radiopharmaceutical precursors. Further isotope exchange reactions yield the F-18 radiopharmaceutical. By adjusting the types of substituents in the substituted alkyl group, this invention can achieve the construction of structurally diverse F-18 radiopharmaceutical precursors with different drug molecules or their derivatives. Furthermore, the prepared F-18 radiopharmaceutical precursors exhibit good stability in aqueous phase and can undergo efficient reactions in aqueous buffer solutions. 18 F- 19 The F isotope exchange reaction avoids the time-consuming dehydration process in the traditional F-18 radiopharmaceutical synthesis, greatly shortening the synthesis time and thus effectively improving the efficiency of F-18 radiopharmaceutical synthesis. 18 F-labeling rate.

The invention relates to the field of biotechnology, medicine and cosmetology, and more particularly to a hybrid matrix for use as a biological graft in the preparation of cardiac prostheses. The technical result of the invention includes improving the surface biocompatibility and the stability and durability of a biological graft which provides an antimicrobial response, and also preventing calcification. A method for producing a hybrid biomatrix comprises the following steps: pre-purifying a base of a biomatrix for 0.75-6 hours in two stages, consisting in the decellularization of xenopericardium in a 2-5 wt% water-alcohol solution of Tween-80, saturated with CO2, at a temperature of 20-400°C and a pressure of 10-30 MPa, and the subsequent decellularization of the xenopericardium in a multi-component system containing a solution based on supercritical CO2 and a 1-1.5 vol% addition of a 2-5 wt% water-alcohol solution of Tween-80, at a temperature of 20-400°C and a pressure of 10-30 MPa; stabilizing the biomatrix base by treatment with a 0.1-0.5 wt% aqueous buffer solution of genipin having a pH of 6.0-7.4 for 3-4 hours; and applying to the pre-purified biomatrix base a coating consisting of an aqueous solution of chitosan nanoparticles with an antimicrobial doping additive in the form of silver or vancomycin nanoparticles in a carbonic acid solution, at a pressure of 20-30 MPa and a temperature of 23-270°C for 1-6 hours.

The present disclosure is directed to methods for characterization of a sample by size exclusion chromatography (SEC), the sample including intact lipid nanoparticles (LNPs). The method generally includes loading the sample on a chromatographic column having an SEC packing material disposed therein, flowing a mobile phase through the SEC packing material to elute the intact LNPs, and detecting the eluted intact LNPs. The mobile phase includes an aqueous buffer and a branched poly-α-d-glucoside.

An aqueous pharmaceutical solution for the treatment of a central nervous system (CNS) disorder is provided, the solution comprising at least 5 mg / ml dissolved levodopa and a pH in the range of 3.0 to 8.5. The solution is provided by mixing: a) an aqueous stock solution comprising levodopa, the stock solution having a pH of less than 2.8 at 25°C, and b) an aqueous buffer solution for increasing the pH of the stock solution, the buffer solution having a pH of at least 4.0 at 25°C. The aqueous pharmaceutical solution is administered to a subject having a central nervous system (CNS) disorder shortly after mixing the aqueous stock solution and the aqueous buffer solution. Further, a kit for administering an aqueous pharmaceutical solution to a subject having a central nervous system (CNS) disorder is provided.

A process for the preparation of a compound of formula (I) wherein R1 is selected from one or more of the following: alkyl, substituted alkyl, haloalkyl, cyanoalkyl, alkoxy, halogen, haloalkoxy, amino, aminoalkyl, alkylsulfonyl, arylsulfonyl, alkylsulfanyl and hydroxyl wherein n is selected from 1, 2 or 3, the process comprises reacting a compound of formula (II) with 2-haloheptafluoropropane in the presence of sodium dithionite (Na2S2O4) and an aqueous buffer, where the aqueous buffer comprises an acid and a base.

The invention is relative to a method for producing a microwave-processed starch or flour comprising the steps consisting of soaking a native starch or flour in an aqueous buffer solution, drying the starch or flour to a moisture content of less than about 2% (wt.%), and heating the dried starch or flour using microwaves at a temperature below 100°C, preferably between 60°C and 90 °C.

This invention discloses a hexavanadate-bridged double-ended click nucleic acid probe construct, its preparation method, and its application, relating to the field of bioanalytical technology. The hexavanadate-bridged double-ended click nucleic acid probe construct comprises a hexavanadate derivative V6-(N3)2 bridging scaffold with azido groups at both ends, and two identical oligonucleotides MB1 or MB2; MB1 is terminally alkyne and labeled with a FAM fluorescent group, and MB2 is terminally alkyne and labeled with a Cy5 fluorescent group; V6-(N3)2 and MB1 or MB2 undergo a Cu(I)-catalyzed azido-alkynyl cycloaddition reaction to form a 1,2,3-triazole linker bond, connecting to form an MB1-triazole-V6-triazole-MB1 or MB2-triazole-V6-triazole-MB2 structure. This invention also discloses a method for preparing this construct, wherein the finished product is obtained through a click reaction in an aqueous buffer system, copper removal and desalting, and separation and purification. And its application in nucleic acid sequence-specific detection, with its fluorescence quantitative readout mechanism, improves the robustness of sequence identification, mismatch detection and quantitative detection, and is suitable for pathogen identification, gene mutation screening, molecular diagnostics and drug companion diagnostics.

The invention relates to a culture medium suitable for cell culture and a preparation method thereof. The media can be prepared essentially by dissolving or mixing individual media components in water or in a suitable aqueous buffer. The important step of culture medium preparation is a sterilization step. The medium according to the invention may comprise a protein hydrolysate as an amino acid source. The invention also provides advantageous methods of hydrolyzing proteins into shorter peptide chains and / or single amino acids.

The invention discloses a preparation method and application of organic semiconductor lipid nanoparticles for near-infrared two-region imaging. The preparation method comprises the following steps: (a) dissolving an organic semiconductor molecule BTP-IC-OD, soybean lecithin SPC, cholesterol Chol and distearoyl phosphatidyl ethanolamine-polyethylene glycol-folic acid DSPE-PEG-FA in an organic solvent to form an organic phase; (b) carrying out reduced pressure rotary evaporation to remove the organic solvent to form a uniform composite film containing the components; (c) adding a water-phase buffer solution to hydrate the composite film to form a crude liposome suspension; and (d) extruding and granulating the crude liposome suspension through a filter membrane with the pore diameter of 80-200nm. The organic semiconductor lipid nanoparticles can clearly draw the boundary of a tumor focus and detect conventional small metastatic lymph nodes which are difficult to find, and a novel tool is provided for early diagnosis of malignant tumors, real-time navigation guide excision in an operation and curative effect monitoring.

Compositions, methods, and kits for stable Trypan Blue solutions are provided. In one example, a method includes: cooling a solution of Trypan Blue; and filtering the cooled solution. In another example, a method includes: mixing a water-soluble polymer with a Trypan Blue solution. The method may further include adding one or more ingredients such as an aqueous buffer, an osmolyte, an acid, a base, a buffer, a cell culture medium, water, or combinations thereof.

A method of quantifying a concentration of a chemical entity in a matrix includes combining an aqueous buffer; a reporter reagent including at least one reporter molecule selectively bindable to the chemical entity; an organic, non-polar extraction solvent including an internal standard entity; a wash buffer; and the matrix to thereby prepare a liquid precursor. The method includes solvent extracting a sample from the liquid precursor. The sample includes at least one of the internal standard entity and a plurality of complexes formed from the chemical entity and the at least one reporter molecule. The method also includes scanning the sample with a surface-enhanced Raman spectrometer to produce a dataset including at least one of a plurality of target spectra of the chemical entity and a plurality of reference spectra of the internal standard entity. The method includes processing the dataset to thereby quantify the concentration of the chemical entity.

The invention belongs to the technical field of natural product extraction, separation and purification, and discloses a purification process for green solvent-assisted extraction of eucalyptus oil and a quality control method. The technology is characterized in that a ternary reaction system composed of a natural deep eutectic solvent, a water-phase buffer system and an immobilized biocatalyst is constructed, purification and function enhancement are synchronously achieved through selective bioconversion of unstable components such as alpha-pinene and limonene, and GC-MS and near infrared spectrum are combined for online monitoring and dynamic feedback regulation. According to the process, the chemical stability and safety of the eucalyptus oil are remarkably improved, new functional attributes are given to the product by precisely regulating and controlling a conversion path, and meanwhile, the batch consistency and process controllability of industrial production are ensured through a matched multi-dimensional quality control method; and a complete technical solution is provided for high-valued and green manufacturing of natural essential oil.

The application relates to the technical field of medical carriers, in particular to a cell dispersion carrier and a preparation method and application thereof. The preparation method comprises the following steps: dissolving a hydrophobic peptide segment in an organic solvent, adding nano-magnetic particles containing a magnetic metal organic framework to perform microwave and ultrasonic synergistic dispersion, and obtaining a composite of the magnetic particles and the hydrophobic peptide segment; in a stable magnetic field, the composite is subjected to magnetic separation to obtain a magnetic separation product; the magnetic separation product is dispersed in an aqueous buffer to obtain a magnetic dispersion liquid; the self-assembled short peptide is dissolved in the magnetic dispersion liquid to perform ultrasonic induction to obtain the cell dispersion carrier. The preparation method is connected through four steps of microwave+ultrasonic synergistic dispersion, anchoring of the hydrophobic peptide segment, magnetic separation in a stable magnetic field and ultrasonic induction self-assembly, and finally, a uniform distribution state is dynamically locked in a gelation process, so that the nano-magnetic MOF particles are uniformly dispersed in the hydrogel matrix from the molecular to the macroscopic full-scale.

The application discloses a method for preparing chiral isoquinoline carboxylic acid (I), which comprises the following steps: reacting a racemate of compound I in an aqueous buffer solution under catalysis of Candida antarctica lipase B to generate a compound shown in formula (I), and performing the reaction at a preset pH value of 7.8-8.2. The method has the characteristics of mild reaction condition, high stereoselectivity, high reaction efficiency, relatively simple process and the like, and has an industrial application prospect.

An anesthetic composition is provided for the local administration of a local anesthetic agent to a subject in need; the anesthetic composition has a lipid-based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH greater than 5.5; a method is also provided for preparing an anesthetic composition using a simpler and more robust method for large-scale manufacturing and for providing a high molar ratio of local anesthetic agent to phospholipid content compared to the prior technique; this anesthetic composition has a prolonged duration of effectiveness tailored to drug administration.

Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with en trapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Usable life of a biosensor life is extended while keeping the sensing system enclosed and minimizing the introduction of flushing solutions into a measurement line (e.g., a blood vessel) of a fluid system, such as a human blood vessel, a nutritional fluid line in a tissue cultivation system, or a circulation system in an organ preservation system. A catheter, tube, or other lumen contains the active biosensor. One end of the lumen is introduced to the target fluid, and the other end is connected to a supply of a buffer solution (e.g., heparinized saline solution). By advancing the buffer solution along the lumen, the biological fluid (e.g., blood) can be purged from the area around the sensor material to halt any reactions. When a measurement is desired, then the buffer solution is withdrawn (e.g., suctioned) back into the supply so that the biological fluid enters and contacts the sensor material.

This invention relates to a culture medium suitable for cell culture and a process for preparing the same. The culture medium can essentially be prepared by dissolving or mixing individual medium components in water or a suitable aqueous buffer. A key step in the preparation of the medium is a sterilization step. The culture medium according to the present invention may contain protein hydrolysates as an amino acid source. A favorable process for protein hydrolysis to shorter peptide chains and / or single amino acids is also provided by this invention.

The present disclosure is directed to methods for characterization of a sample by size exclusion chromatography (SEC), the sample including intact lipid nanoparticles (LNPs). The method generally includes loading the sample on a chromatographic column having an SEC packing material disposed therein, flowing a mobile phase through the SEC packing material to elute the intact LNPs, and detecting the eluted intact LNPs. The mobile phase includes an aqueous buffer and a branched poly-α-d-glucoside.

The invention discloses a tannic acid-rich plant extract obtained by a water extraction process as well as a method and application thereof, and belongs to the technical field of natural product extraction and animal feed additives. The method comprises the following steps: crushing a tannin-containing plant material, adding the crushed tannin-containing plant material into a water-based buffer solution with the pH value of 5.0-7.0, and carrying out water extraction to obtain an extracting solution; concentrating the extracting solution to obtain a concentrated solution, adding a demulsifying agent and a precipitating agent into the concentrated solution, and standing and precipitating; filtering the supernate by adopting an ultrafiltration membrane to obtain a permeate and a concentrated solution; and drying the permeate to obtain the tannic acid-rich plant extract. A water extraction process is adopted, and waste liquid can be biochemically treated; after the purity of tannic acid in the obtained extract is high, active ingredients are completely reserved; through the intestinal convergence effect of tannic acid, the extract can significantly adjust the animal intestinal microflora structure, improve the intestinal barrier function and reduce inflammatory response, and can be used as an antibiotic substitute for livestock and poultry breeding.

An embolic hydrogel for use with a patient comprise an aqueous buffer and at least one functionalized polymer respectively having at least one polymer backbone chemically modified with one or more functional groups. The functional group(s) facilitate formation of primary reversible crosslinks on the polymer backbone(s), such that the embolic hydrogel transitions from a gel state to a viscous liquid state in response to a shear force applied to the embolic hydrogel, and transitions from the viscous liquid state back to the gel state in response to an absence of a shear force applied to the embolic hydrogel. The embolic hydrogel further comprises at least one phase-transitioning polymer that creates secondary crosslinks therein in response to a physiological environment, such that the embolic hydrogel transitions from the gel state to a solid state.

A method of making heterogeneous biocatalysts can include admixing a protein dissolved in an aqueous buffer with an imprinting compound dissolved in a water-immiscible imprinting solvent, wherein the imprinting compound is hydrophobic and enters and remains in the active site of the protein due to hydrophobic interaction. A water-miscible organic solvent can then be added to precipitate the protein having the imprinting compound in the active site as an amorphous solid. The precipitate can be separated and lyophilized and then washed to remove the imprinting compound, thereby providing a heterogeneous biocatalyst.

The present disclosure is directed to methods for characterization of a sample by size exclusion chromatography (SEC), the sample including intact lipid nanoparticles (LNPs). The method generally includes loading the sample on a chromatographic column having an SEC packing material disposed therein, flowing a mobile phase through the SEC packing material to elute the intact LNPs, and detecting the eluted intact LNPs. The mobile phase includes an organic solvent, an aqueous buffer, and a non-ionic surfactant.

An embolic hydrogel for use with a patient comprise an aqueous buffer and at least one functionalized polymer respectively having at least one polymer backbone chemically modified with one or more functional groups. The functional group(s) facilitate formation of primary reversible crosslinks on the polymer backbone(s), such that the embolic hydrogel transitions from a gel state to a viscous liquid state in response to a shear force applied to the embolic hydrogel, and transitions from the viscous liquid state back to the gel state in response to an absence of a shear force applied to the embolic hydrogel. The embolic hydrogel further comprises at least one phase-transitioning polymer that creates secondary crosslinks therein in response to a physiological environment, such that the embolic hydrogel transitions from the gel state to a solid state.

The invention belongs to the technical field of food engineering, and discloses a pH-responsive intestinal targeted sustained-release flavone liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) mixing the lipid A and the lipid B to form an organic phase solution, and mixing the organic phase solution and a water phase buffer solution in a microfluidic manner to prepare a blank liposome L; (2) adding a buffer solution to adjust the pH value of the external water phase of the blank liposome L to 7.0-7.4, dissolving flavone in the buffer solution with the pH value of 7.0-7.4 to form a flavone water phase, and mixing the blank liposome L with the external water phase with the pH value of 7.0-7.4 with the flavone water phase in a microfluidic manner to prepare liposome LF; (3) mixing the lipidosome LF and a chitosan solution in a micro-fluidic manner, so as to prepare lipidosome CH-LF; (4) mixing the lipidosome CH-LF with a sodium alginate solution in a micro-fluidic manner, so as to prepare a lipidosome SA-CH-LF; and (5) freeze-drying the liposome SA-CH-LF to obtain a flavone liposome finished product.